Clinical Data and Pharmacokinetics of a Docetaxel-vinorelbine Combination in Anthracycline Resistant/Relapsed Metastatic Breast Cancer

References

• Mick R, Begg CB, Antman KH, Korzun AH, Frei III E. Diverse prognosis in metastatic breast cancer: who should be offered alternative initial therapies? Breast Cancer Res Treat 1989; 13: 33–8.
   Google Scholar
• Gasparini G, Caffo O, Barni S, et al. Vinorelbine is an active anti-proliferative agent in pre-treated advanced breast cancer patients: a phase II study. J Clin Oncol 1994; 12: 2094–101.
   PubMed Web of Science ®Google Scholar
• Jones S, Winer E, Vogel C, et al. Randomized comparison of vinorelbine and melphalan in anthracycline-refractory ad-vanced breast cancer. J Clin Oncol 1995; 13: 2567–74.
   PubMed Web of Science ®Google Scholar
• Van Oosterom AT. Docetaxel (Taxotere): an effective agent in the management of second-line breast cancer. Sem Oncol 1995; 22: 22–8.
   PubMedGoogle Scholar
• O'Brien MER, Leonard RC, Barrett-Lee PJ, Eggleton SPH, Bizzarri SP Docetaxel in the community setting: an analysis of 377 breast cancer patients treated with docetaxel (Taxotere) in the UK. Ann Oncol 1999; 10: 205–10.
   PubMedGoogle Scholar
• Crown J. Phase III randomized trials of docetaxel in patients with metastatatic breast cancer. Semin Oncol 1999; 26(Suppl 8): 33–8.
   PubMedGoogle Scholar
• Aoe K, Kiura K, Ueoka H, et al. Effect of docetaxel with cisplatin or vinorelbine on lung cancer lines. Anticancer Res 1999; 19: 291–300.
   PubMed Web of Science ®Google Scholar
• Hino M, Kobayashi K, Hayashihara K, et al. In vitro combination effect of docetaxel with vinca alkaloids on cancer cell line. Proc Am Assoc Cancer Res 1995; 36: 299 (Abstr 1780).
   Google Scholar
• Ceruti M, Tagini V, Recalenda V, et al. Docetaxel in combina-tion with epirubicin in metastatic breast cancer: pharmacoki-netic interactions. II Farmaco 1999; 54: 733–9.
   PubMedGoogle Scholar
• Villani F, Misrachi D, Galimberti M. Cardiac arrhythmia and ischaemic events after combination chemotherapy for testicular cancer. Eur Heart J 1994; 15: 1533–6.
   Google Scholar
• Krug LM, Kris MG, Grant SC, et al. Phase II trial of dose dense docetaxel plus vinorelbine with prophylactic Filgrastim (G-CSF) in advanced non small cell lung cancer. Proc Am Soc Clin Oncol 1999; 18: 460 (Abstr 1775).
   Google Scholar
• Alexandre J, Bleuzen P, Bonneterre J, et al. Factors predicting for efficacy and safety of docetaxel in a compassionate-use cohort of 825 heavily pretreated advanced breast cancer patients. J Clin Oncol 2000; 18: 5 62–7 3.
   Google Scholar
• Bueso P. Mayordomo JI, Cajal R, et al. Final report of a phase II trial with docetaxel + vinorelbine for anthracycline-refrac-tory metastatic breast cancer. Eur J Cancer 1999; 35 (Suppl 2): S53 (Abstr no. 24).
   Google Scholar
• Galvez C. Doxetaxel (D) in combination with vinorelbine (VNB) with GM-CSF in taxol refractory metastatic breast cancer (MBC). Preliminary results of phase II. Eighth Int Congr on Anti-Cancer Treatment; Feb 3–6 1998; Paris, France, 165 (Abstr no. P 119).
   Google Scholar
• Oncopaz Cooperative Group Study. Docetaxel-vinorelbine in anthracycline resistant disseminated breast carcinoma. An Oncopaz Cooperative Group Study. Eur J Cancer 1999; 35 (Suppl 2): S52 (Abstr no. 10).
   Google Scholar
• Llombart-Cussac A, Spielmann M, Dohollou N, Le Cesne A, Rixe O. Cis-platinum-taxotere phase I/II trial in patients with anthracyclin-resistant advanced breast cancer (ABC). Proc Am Soc Clin Oncol 1997; 16: 180a (Abstr no. 629).
   Google Scholar
• Salimi M, Mir MR. Dose-dense weekly docetaxel and CBDCA in adriamycin-resistant metastatic breast cancer (MBC). Eur J Cancer A 1998; 34 (Suppl 5): S44 (Abstr no. 178).
   Google Scholar
• Lortholary A, Maillart P, Delva R. Docetaxel (D) in combina-tion with continuous infusion 5-fluorouracil (CI 5FU) in metastatic breast cancer (MBC) patients (pts) after anthracy-cline (ANT) failure: phase I dose-escalation. Breast Cancer Res Treat 1997; 46: 96 (Abstr no. 413).
   Google Scholar
• Mavroudis D, Malamos N, Alexopoulos A, et al. Salvage chemotherapy in anthracycline-pretreated metastatic breast cancer patients with docetaxel and gemcitabine: a multicenter phase II trial. Ann Oncol 1999; 10: 211–5.
   PubMed Web of Science ®Google Scholar
• Burris III HA. Single-agent docetaxel (taxotere) in randomized phase III trials. Sem Oncol 1999; 26(Suppl 9): 1–6.
   Google Scholar
• Jehl F, Quoix E, Leveque D, et al. Pharmacokinetic and preliminary metabolic fate of navelbine in humans as deter-mined by high performance liquid chromatography. Cancer Res 1991; 51: 2073–6.
   PubMed Web of Science ®Google Scholar
• Marre F, Sanderink G-J, de Sousa G, Gaillard C, Martinet M, Rahmani R. Hepatic biotransformation of docetaxel in vitro: involvement of CYP3A sub-family in humans. Cancer Res 1996; 56: 12 9 6–302.
   Google Scholar
• Horwitz SB, Cohen D, Rao S, Ringel I, Shen HJ, Yang CP Taxol: mechanisms of action and resistance. J Natl Cancer Inst Monogr 1993; 15: 5 5–6 1 .
   Google Scholar
• Zhou X-J, Rahmani R. Preclinical and clinical pharmacology of Vinca alkaloids. Drugs 1992; 44: 1–16.
   Google Scholar
• D'Incalci M, Schuller J, Colombo T, Zucchetti M, Riva A. Taxoids in combination with anthracyclines and other agents: pharmacokinetic considerations. Semin Oncol 1998; 25(Suppl 13): 16–20.
   PubMedGoogle Scholar
• Leveque D, Jehl F Clinical pharmacokinetics of vinorelbine. Clin Pharmacokinet 1996; 31: 184–97.
   PubMed Web of Science ®Google Scholar
• Cattel L, Recalenda V, Airoldi M, Tagini V, Arpicco S, Brusa P, Bumma C. A sequence-dependent combination of docetaxel and vinorelbine: pharmacokinetic interactions. II Farmaco 2001; 56: 779–84.
   Google Scholar
• Woodcock DM, Linsenmeyer ME, Choymowski G, et al. Reversal of multidrug resistance by surfactants. Br J Cancer 1992; 66: 62–8.
   PubMed Web of Science ®Google Scholar